Form 4: uniQure Executive Sells Shares Under 10b5-1 Plan

uniQure's Chief Medical Officer, Walid Abi-Saab, executed a series of stock transactions under a pre-arranged 10b5-1 plan, selling a total of 45,000 ordinary shares.

Summary

• Walid Abi-Saab, Chief Medical Officer of uniQure N.V., reported transactions involving the sale of uniQure ordinary shares.
• These transactions were conducted under a Rule 10b5-1 sales plan adopted on September 26, 2025.
• A total of 45,000 ordinary shares were disposed of in multiple transactions.
• The sales occurred on May 8, 2026, with a weighted average sale price of $25.10 per share, ranging from $25.00 to $25.29.
• Following these sales, Mr. Abi-Saab beneficially owns 169,669 ordinary shares directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the significant sale of shares by a key executive, even though it was conducted under a pre-planned 10b5-1 strategy.

Negatives

• The Chief Medical Officer sold a significant number of shares (45,000) under a pre-arranged plan.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future company performance. It solely reports past transactions.

Management Comments

• The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
• The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.29. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• The Stock Option was granted on March 1, 2024 and vested 25% on the first anniversary of the date of grant, and vests 6.25% quarterly thereafter until fully vested.

Industry Context

StockSavvy.ai notes that Form 4 filings reporting insider stock sales, especially under 10b5-1 plans, are common in the biotechnology sector as executives manage personal portfolios. While these plans are designed to avoid insider trading concerns, significant sales can sometimes be interpreted by the market as a lack of confidence, regardless of the underlying reasons.

Stakeholder Impact

• Shareholders may view the sale of a substantial number of shares by the Chief Medical Officer negatively, potentially impacting short-term stock price sentiment, despite the sale being executed under a Rule 10b5-1 plan.

Key Dates

Recommendation

The filing reports routine stock sales by an executive under a 10b5-1 plan, which is a standard practice. While the sale of 45,000 shares is notable, it does not provide new information about the company's fundamental performance or future prospects. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial updates from the company.

Keywords

uniQure, QURE, Form 4, insider trading, 10b5-1 plan, stock sale, executive compensation, beneficial ownership